AVA6103 for advanced FAP-positive solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cancer known to be FAP-positive, such as cervical, vulvar, small cell lung, stomach, pancreatic, colorectal, or hormone receptor-positive breast cancer.
- Your cancer is locally advanced (cannot be surgically removed) or has spread to other parts of the body, and you have already tried standard treatments or cannot take them.
- You are generally active (able to do light work or fully active).
- Your major organs (kidneys, liver, bone marrow) are working well enough based on recent blood tests.
- You are not pregnant and agree to use effective contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This study tests a new mRNA vaccine that targets a protein called FAP, which is found in many solid tumors. It is for people whose cancer has not responded to or cannot tolerate standard treatments.
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.